Propofol inhibits the malignant development of osteosarcoma U2OS cells via AMPK/FΟΧO1-mediated autophagy

Lina Dai1, Shimei Li1, Xi Li1

  • 1Department of Anesthesiology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550001, P.R. China.

Oncology Letters
|August 11, 2022
PubMed

Insights

Propofol inhibits osteosarcoma (OS) cell development by promoting autophagy through the adenosine monophosphate-activated protein kinase (AMPK)/FOXO1 pathway. This study reveals propofol

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Propofol's role in osteosarcoma (OS) development is known, but its precise molecular mechanisms are unclear.
  • Understanding propofol's effects on OS is crucial for potential therapeutic applications.

Purpose of the Study:

  • To investigate the effects of propofol on human osteosarcoma U2OS cells.
  • To elucidate the underlying molecular mechanisms, focusing on autophagy and the AMPK/FOXO1 signaling pathway.

Main Methods:

  • Cell viability and proliferation assessed by Cell Counting Kit-8 and colony formation assays.
  • Apoptosis evaluated using TUNEL assay and western blotting.
  • Migration, invasion, and epithelial-mesenchymal transition (EMT) analyzed via wound healing, Transwell assays, and western blotting for related proteins.

Main Results:

  • Propofol significantly reduced OS cell viability and proliferation in a dose-dependent manner.
  • Propofol treatment enhanced autophagy and promoted apoptosis.
  • Propofol upregulated phosphorylated AMPK and FOXO1, while downregulating phosphorylated FOXO1, suppressing EMT, migration, and invasion.

Conclusions:

  • Propofol exhibits an inhibitory effect on osteosarcoma development.
  • The mechanism involves propofol-induced autophagy via the AMPK/FOXO1 signaling pathway.
  • Findings provide a basis for exploring propofol as a potential therapeutic agent for OS.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K